Table 1. Baseline characteristics of the studied population.
| All | TDF+/NNRTI | TDF+/rbPI | TDF-/NNRTI | TDF-/rbPI | Other | ||
|---|---|---|---|---|---|---|---|
| N (%) | 6301 | 1183 (19) | 2360 (37) | 285 (5) | 1606 (25) | 867 (14) | |
| Age (years) at ART initiation, median (IQR) | 39 (32–47) | 38 (32–46) | 40 (32–47) | 39 (32–48) | 37 (30–46) | 40 (33–48) | |
| Baseline eGFR (ml/min/1.73m2), median (IQR) | 101 (86–118) | 102 (87–117) | 102 (88–119) | 91 (81–110) | 100 (84–121) | 100 (87–117) | |
| Baseline CD4 count (cells/mm3), median (IQR) | 289 (175–392) | 325 (245–430) | 276 (147–385) | 272 (207–331) | 275 (164–373) | 298 (144–413) | |
| Baseline HIV-1 viral load (log10.copies/ml), median (IQR) | 4.8 (4.2–5.3) | 4.7 (4.1–5.1) | 4.9 (4.4–5.4) | 4.8 (4.3–5.2) | 4.8 (4.2–5.3) | 4.8 (4.2–5.3) | |
| Nadir CD4 count (cells/mm3), median (IQR) | 264 (148–358) | 304 (218–391) | 253 (130–359) | 251 (164–314) | 246 (132–338) | 268 (119–366) | |
| Gender | Male, n (%) | 4583 (73) | 939 (79) | 1813 (77) | 212 (74) | 967 (60) | 652 (75) |
| HIV exposure | Homosexual, n (%) | 2812 (45) | 646 (55) | 1122 (48) | 119 (42) | 527 (33) | 398 (46) |
| Heterosexual, n (%) | 2803 (45) | 422 (36) | 1000 (42) | 139 (49) | 905 (56) | 337 (39) | |
| Other or unknown, n (%) | 686 (11) | 115 (10) | 238 (10) | 27 (10) | 174 (11) | 132 (15) | |
| Hepatitis B, n (%) | 317 (5) | 60 (5) | 159 (7) | 6 (2) | 39 (2) | 53 (6) | |
| Hepatitis C, n (%) | 459 (7) | 72 (6) | 192 (8) | 19 (7) | 97 (6) | 79 (9) | |
| Hypertension, n (%) | 247 (4) | 44 (4) | 77 (3) | 14 (5) | 79 (5) | 33 (4) | |
| CVD, n (%) | 102 (2) | 14 (1) | 41 (2) | 9 (3) | 20 (1) | 18 (2) | |
| Diabetes, n (%) | 113 (2) | 21 (2) | 30 (1) | 10 (4) | 33 (2) | 19 (2) | |
| rbPI or NNRTI component of initial ART regimen, n (%) | |||||||
| Efavirenz | 989 (84) | 172 (30) | |||||
| Nevirapine | 95 (8) | 106 (37) | |||||
| Etravirine | 14 (1) | 7 (2) | |||||
| Rilpivirine | 85 (7) | 0 | |||||
| rDarunavir | 911 (39) | 258 (16) | |||||
| rAtazanavir | 669 (28) | 251 (16) | |||||
| rLopinavir | 626 (27) | 855 (53) | |||||
| rFosamprenavir | 101 (4) | 169 (11) | |||||
| rSaquinavir | 50 (2) | 43 (3) | |||||
| rTipranavir | 3 (0) | 0 | |||||